These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7518341)

  • 21. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer.
    D'Amico AV; Hanks GE
    Cancer; 1993 Nov; 72(9):2638-43. PubMed ID: 7691393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
    Pollack A; Lankford S; Zagars GK; Babaian RJ
    Cancer; 1996 Apr; 77(8):1515-23. PubMed ID: 8608537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
    Nakata S; Takezawa Y; Kobayashi M; Kuribara H; Matumoto K; Kosaku N; Suzuki T; Yamanaka H
    Nihon Rinsho; 1998 Aug; 56(8):2026-30. PubMed ID: 9750501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
    J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiotherapy for regionally localized hormone refractory prostate cancer.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):907-12. PubMed ID: 7591901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PSA-related parameters in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2002 Sep; 93(6):686-93. PubMed ID: 12385093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma.
    Bellavita R; Massetti M; Abraha I; Lupattelli M; Mearini L; Falcinelli L; Farneti A; Palumbo I; Porena M; Aristei C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e299-304. PubMed ID: 22572075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
    J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.